Clinical trials: Oligometastatic Prostate Carcinoma
Prostate Cancer
SBRT for Oligometastatic Castration-Refractory Prostate Cancer
Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions.
- Trial name
- NCT02816983
- Testing
- SBRT
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Prostate Cancer Metastatic, Radiation Therapy
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
The study is an open label, multi-centre, randomized phase III study. The patients will be randomised in a 1:1 ratio to treatment consisting of Arm A: MD-SBRT in addition to standard treatment Arm B: Standard treatment Study…
- Conditions
- Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography
- Trial name
- METRO (NCT04983095)
- Testing
- stereotactic body radiotherapy, androgen deprivation therapy, Radiotherapy
- Where
- 7 sites in Sweden
- Volunteers
- 118 people
- Sponsor
- Karin Soderkvist
Hormone Sensitive Oligometastatic Prostate Cancer
Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer
Patients with hormone sensitive oligometastatic prostate cancer (≤ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with…
- Trial name
- PRORAD (NCT03301701)
- Testing
- Radical prostatectomy, HDR (19Gy) or SBRT (35-40Gy)
- Where
- Canada
- Sponsor
- Dr. Patrick Cheung
Prostatectomy, Oligometastatic Prostate Cancer
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
This randomized, controlled, multi-center clinical trial aims to evaluate the efficacy and safety of prostatectomy for castration-Naive oligometastatic prostate cancer
- Conditions
- Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone
- Trial name
- NCT04992026
- Testing
- robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection, 1.Abiraterone Acetate Tablets, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Prostate Cancer Recurrent
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed…
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- SPARKLE (NCT05352178)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
- Where
- Belgium
- Volunteers
- 873 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer, Oligometastatic Prostate Cancer
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
This study is a multicenter, randomized controlled phase III clinical trial (PROLONG-3) designed to evaluate the survival benefit of comprehensive radiotherapy combined with primary tumor radiotherapy versus primary tumor…
- Trial name
- PROLONG-3 (NCT07015138)
- Testing
- TRT, NTRT
- Where
- 3 sites in China
- Volunteers
- 390 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- oligo-mets (NCT02716974)
- Testing
- Leuprolide Acetate, Bicalutamide, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone.
- Trial name
- LUST (NCT05893381)
- Testing
- [177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than…
- Trial name
- NCT02742675
- Testing
- Bicalutamide, goserelin acetate, flutamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
This phase II trial studies how well androgen deprivation therapy and apalutamide with or without radiation therapy works for the treatment of prostate cancer that has a rise in the blood level of prostate-specific antigen (PSA)…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04585932
- Testing
- Apalutamide, Degarelix, Leuprolide Acetate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- PILLAR (NCT03503344)
- Testing
- Apalutamide, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Prostate Cancer Patients, Non-castrate Prostate Cancer
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells.
- Conditions
- Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
- Trial name
- NCT07090148
- Testing
- pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
High-Risk and Oligometastatic Prostate Cancer
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.
- Trial name
- NCT04997252
- Testing
- Apalutamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhujiang Hospital
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT00544830
- Testing
- Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Metastatic Prostate Cancer
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
This is a multi-centre, investigator-initiated, three-arm, randomized trial to investigate the addition on androgen receptor pathway inhibitor and atorvastatin to standard of care radiation and hormone therapy improve quality of…
- Trial name
- DIRECT (NCT05404139)
- Testing
- Abiraterone, Standard of Care SBRT and ADT, Atorvastatin
- Where
- 2 sites in Canada
- Volunteers
- 352 people
- Sponsor
- University Health Network, Toronto
Cancer Patients Receiving Stereotactic Body RTX
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
This prospective protocol will enroll patients with pathologically confirmed solid malignancies who receive stereotactic body radiation therapy (SBRT) for oligometastases, for consolidation after systemic therapy, prior to…
- Trial name
- NCT02170181
- Testing
- SBRT
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer, Radiotherapy Side Effect
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
- Trial name
- SMART-P01/02 (NCT05183074)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223.
- Trial name
- RAVENS (NCT04037358)
- Testing
- Radium-223, stereotactic ablative radiotherapy (SABR)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph…
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06389786
- Testing
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic